-
Product Insights
Sicca Syndrome (Sjogren) – Drugs In Development, 2023
Global Markets Direct’s, ‘Sicca Syndrome (Sjogren) - Drugs In Development, 2023’, provides an overview of the Sicca Syndrome (Sjogren) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2023’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Mild Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Mild Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Mild Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Dementia Associated With Alzheimer’s Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Dementia Associated With Alzheimer's Disease - Drugs In Development, 2023’, provides an overview of the Dementia Associated With Alzheimer's Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Dementia Associated With Alzheimer's Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Cognitive Impairment – Drugs In Development, 2023
Global Markets Direct’s, ‘Cognitive Impairment - Drugs In Development, 2023’, provides an overview of the Cognitive Impairment pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LAVA-1207 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LAVA-1207 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.LAVA-1207 in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details:LAVA-1207 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NUV-655 in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NUV-655 in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.NUV-655 in Esophageal Squamous Cell Carcinoma (ESCC) Drug Details:NUV-655 is...
-
Product Insights
Sicca Syndrome (Sjogren) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Sicca Syndrome or Sjogren's syndrome is an autoimmune disease. It involves inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease. The Sicca Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Sicca Syndrome, complete with analysis by stage of development, drug target, mechanism...
-
Product Insights
Non-Hodgkin Lymphoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Non-Hodgkin lymphoma (also known as non-Hodgkin’s lymphoma, NHL, or sometimes just lymphoma) is a cancer that starts in cells called lymphocytes, which are part of the body’s immune system. Symptoms may include night sweats, fever and chills that come and go, itching, putting pressure on the windpipe (trachea) or other airways, abdominal pain or swelling, leading to loss of appetite, constipation, nausea, and vomiting and headache, concentration problems, personality changes, or seizures if cancer affects the brain. Treatment includes surgery,...
-
Product Insights
Systemic Lupus Erythematosus Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Systemic Lupus Erythematosus Pipeline Drugs Market Report Overview The inflammation triggered by Systemic Lupus Erythematosus (SLE) affects many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender, and hormones. The Systemic Lupus Erythematosus pipeline market research report provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route...